Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CAH
CAH logo

CAH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
210.410
Open
208.400
VWAP
209.02
Vol
407.98K
Mkt Cap
48.55B
Low
207.260
Amount
85.28M
EV/EBITDA(TTM)
14.31
Total Shares
235.32M
EV
54.98B
EV/OCF(TTM)
9.01
P/S(TTM)
0.20
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
Show More

Events Timeline

(ET)
2026-03-23
07:20:00
Cardinal Health Appoints Patricia Hemingway Hall as Board Chair
select
2026-02-05 (ET)
2026-02-05
16:50:00
Major Averages Broadly Lower as Investors Grow Cautious on Tech Stocks
select
2026-02-05
10:00:00
McKesson and Others See Notable Stock Gains
select

News

CNBC
6.5
03-27CNBC
CNBC Investing Club March Meeting Overview
  • Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
  • AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
  • Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
  • Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
CNBC
5.0
03-25CNBC
Jim Cramer's Trust Increases Stake in Cardinal Health
  • Increased Stake: Jim Cramer's Charitable Trust purchased 25 shares of Cardinal Health at approximately $210, raising its total holdings to 475 shares and increasing its portfolio weighting from 2.5% to 2.6%, reflecting confidence in the company.
  • Market Reaction: Cardinal Health's stock has pulled back about 9% since the onset of the conflict with Iran; however, the company is expected to see earnings per share grow approximately 25% in the current fiscal year, indicating strong profitability amid market volatility.
  • Product Growth: Sales of GLP-1 medications have provided a significant tailwind to Cardinal's Pharmaceutical and Specialty Solutions business, contributing 6 percentage points to revenue growth in the most recent quarter, further solidifying its market position.
  • Board Changes: The sudden retirement of Chairman Gregory Kenny, replaced by current director Patricia Hemingway Hall, may unsettle investors; however, the company clarified that this decision was not related to operational disagreements and maintains confidence in its future financial outlook.
PRnewswire
9.5
03-24PRnewswire
Cardinal Health to Release Q3 FY2026 Financial Results on April 30
  • Earnings Release Schedule: Cardinal Health is set to release its third-quarter financial results for fiscal year 2026 on April 30, prior to the opening of trading on the New York Stock Exchange, ensuring timely access to critical information for investors.
  • Webcast Discussion: The company will host a webcast discussion of the financial results starting at 8:30 a.m. Eastern, allowing investors to participate by visiting Cardinal Health's Investor Relations page without requiring an access code, thereby enhancing information transparency.
  • Availability of Materials: Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months, facilitating easy access for investors to review the information at their convenience and strengthening communication between the company and its investors.
  • Company Overview: Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a supplier of home-health and direct-to-patient services, and is committed to driving continuous improvement and innovative solutions that enhance people's lives through a customer-centric focus.
Newsfilter
5.0
03-23Newsfilter
Cardinal Health Appoints New Board Chair
  • Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, who has served since 2007 and as Chairman since 2018, during which he supported the company through significant transformations in strategic portfolio evolution and operational improvements.
  • Experienced Leadership: Hemingway Hall has been on the Cardinal Health Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing extensive healthcare leadership experience and deep institutional knowledge that will aid in executing the company's strategic priorities.
  • Positive Financial Outlook: The company is set to release its third-quarter fiscal 2026 earnings on April 30, maintaining confidence in its fiscal 2026 outlook, which indicates stability and growth potential in the current market environment.
  • Commitment to Continuous Improvement: Cardinal Health emphasizes a customer-centric approach, striving for operational efficiency through innovative solutions that enhance lives, showcasing its leadership position in the distribution and services of healthcare products.
PRnewswire
5.0
03-23PRnewswire
Cardinal Health Appoints New Board Chair
  • Board Leadership Change: Cardinal Health has appointed Patricia A. Hemingway Hall as Chair of the Board, succeeding the retiring Gregory B. Kenny, marking a significant governance shift aimed at continuing the execution of strategic priorities.
  • Rich Leadership Experience: Hemingway Hall has been on the Board since 2013 and served as Chair of the Governance and Sustainability Committee for nearly seven years, bringing valuable governance and strategic knowledge from her extensive background in the healthcare sector.
  • Ongoing Strategic Execution: CEO Jason Hollar expressed anticipation for Hemingway Hall to continue Kenny's legacy, focusing on strong governance and long-term value creation, ensuring the company maintains its competitive edge in future market conditions.
  • Earnings Release Preview: Cardinal Health plans to release its third-quarter fiscal 2026 earnings on April 30, with management expressing confidence in the outlook for fiscal 2026, demonstrating the company's resilience in an uncertain market environment.
CNBC
4.5
03-21CNBC
Stock Market Declines Amid Rising Inflation and Geopolitical Tensions
  • Market Decline: The S&P 500, Nasdaq, and Dow have experienced their fourth consecutive week of losses, with declines of 1.5% and approximately 2% respectively, reflecting investor concerns over economic outlook amid the Iran war and rising wholesale inflation.
  • Inflation Concerns: The producer price index rose 0.7% in February, significantly above the expected 0.3%, with Fed Chair Jerome Powell indicating that inflation is not decreasing as hoped, and the spike in oil prices is expected to exacerbate this trend, creating a 'one-two punch' for the market.
  • Memory Shortage Impact: Micron reported nearly tripled revenue but cited structural supply constraints, with CEO stating they can only meet 50% to two-thirds of major customers' needs, leading to increased pressure on hardware companies from rising memory costs.
  • Nvidia GTC Highlights: Nvidia's GTC conference revealed expectations of $1 trillion in orders for Blackwell and Vera Rubin chips by 2027, yet the stock fell 4% despite positive announcements, indicating a complex market reaction to AI chip demand.
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
Wall Street analysts forecast CAH stock price to rise
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
209.00
Averages
225.18
High
244.00
Current: 0.000
sliders
Low
209.00
Averages
225.18
High
244.00
Barclays
NULL -> Overweight
maintain
$243 -> $258
AI Analysis
2026-02-24
Reason
Barclays
Price Target
$243 -> $258
AI Analysis
2026-02-24
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Cardinal Health to $258 from $243 and keeps an Overweight rating on the shares. The firm upped estimates to reflect strength across Cardinal's business. The company's guidance and consensus estimates "remain in a reasonable place," the analyst tells investors in a research note.
Wells Fargo
NULL -> Overweight
maintain
$237 -> $256
2026-02-10
Reason
Wells Fargo
Price Target
$237 -> $256
2026-02-10
maintain
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Cardinal Health to $256 from $237 and keeps an Overweight rating on the shares. The firm is also increasing estimates following Q2 results with strong results in all segments. Strength in Pharmaceutical and Specialty remains particularly notable and the first half of 2026 trajectory suggests upside potential in the second half.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CAH
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cardinal Health Inc (CAH.N) is 20.58, compared to its 5-year average forward P/E of 13.17. For a more detailed relative valuation and DCF analysis to assess Cardinal Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
13.17
Current PE
20.58
Overvalued PE
15.87
Undervalued PE
10.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.87
Current EV/EBITDA
13.51
Overvalued EV/EBITDA
10.50
Undervalued EV/EBITDA
7.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.11
Current PS
0.19
Overvalued PS
0.14
Undervalued PS
0.08

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

us stocks only
Intellectia · 17 candidates
Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 5 - 40Is Index Component: GSPC, RUT, DJI, NDXOne Week Predict Return: 0.0% - 100.0%News Driver: Positive
Ticker
Name
Market Cap$
top bottom
MPC logo
MPC
Marathon Petroleum Corp
64.06B
MCD logo
MCD
McDonald's Corp
232.62B
CVX logo
CVX
Chevron Corp
378.92B
CAH logo
CAH
Cardinal Health Inc
50.83B
REPX logo
REPX
Riley Exploration Permian Inc
698.78M
CRMD logo
CRMD
CorMedix Inc
498.02M
strong buy best stock to trade next week ?
Intellectia · 84 candidates
Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNASOne Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
ECL logo
ECL
Ecolab Inc
86.95B
ASND logo
ASND
Ascendis Pharma A/S
14.47B
WBS logo
WBS
Webster Financial Corp
11.63B
NU logo
NU
Nu Holdings Ltd
72.74B
MP logo
MP
MP Materials Corp
10.46B
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.94T
what stock should i buy on the 27th
Intellectia · 58 candidates
Market Cap: >= 10.00BQuarter Revenue Yoy Growth: >= 10.0%Pe Ttm: 10 - 40List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
SMCI logo
SMCI
Super Micro Computer Inc
18.65B
BG logo
BG
Bunge Global ltd
23.71B
AMCR logo
AMCR
Amcor PLC
23.19B
MU logo
MU
Micron Technology Inc
470.47B
CME logo
CME
CME Group Inc
115.04B
DTE logo
DTE
DTE Energy Co
30.36B
give me 10 strong buy stocks
Intellectia · 2 candidates
Market Cap: >= 10.00BRevenue Ttm: >= 5.00BDividend Yield Ttm: >= 1Themes: Pharmaceutical RetailersAnalyst Consensus: Strong Buy
Ticker
Name
Market Cap$
top bottom
CVS logo
CVS
CVS Health Corp
103.45B
CAH logo
CAH
Cardinal Health Inc
49.53B

Whales Holding CAH

O
Old Republic International Corporation
Holding
CAH
+9.65%
3M Return
P
Pacer Advisors, Inc.
Holding
CAH
+8.18%
3M Return
D
Distillate Capital Partners LLC
Holding
CAH
+1.19%
3M Return
E
Empyrean Capital Partners, LP
Holding
CAH
+1.13%
3M Return
V
Voloridge Investment Management, LLC
Holding
CAH
+1.09%
3M Return
L
Leap Investments LP
Holding
CAH
+0.62%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cardinal Health Inc (CAH) stock price today?

The current price of CAH is 209.4 USD — it has increased 1.5

What is Cardinal Health Inc (CAH)'s business?

Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.

What is the price predicton of CAH Stock?

Wall Street analysts forecast CAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAH is225.18 USD with a low forecast of 209.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cardinal Health Inc (CAH)'s revenue for the last quarter?

Cardinal Health Inc revenue for the last quarter amounts to 65.63B USD, increased 18.75

What is Cardinal Health Inc (CAH)'s earnings per share (EPS) for the last quarter?

Cardinal Health Inc. EPS for the last quarter amounts to 1.97 USD, increased 19.39

How many employees does Cardinal Health Inc (CAH). have?

Cardinal Health Inc (CAH) has 57700 emplpoyees as of March 31 2026.

What is Cardinal Health Inc (CAH) market cap?

Today CAH has the market capitalization of 48.55B USD.